Please login to the form below

Not currently logged in
Email:
Password:

Corlanor

This page shows the latest Corlanor news and features for those working in and with pharma, biotech and healthcare.

Amgen agrees to take Cytokinetics' heart failure drug into phase III

Amgen agrees to take Cytokinetics' heart failure drug into phase III

It sits among a new generation of heart failure therapies - spearheaded by Novartis' Entresto (sacubitril/valsartan) and Amgen/Servier's Corlanor (ivabradine) - which are trying to advance the treatment of heart

Latest news

  • FDA clears Amgen's Corlaner for heart failure FDA clears Amgen's Corlaner for heart failure

    Corlaner's approval is based on the results of the phase III SHIFT trial, which compared Corlanor to placebo, in addition to standard of care, in more than 6500 patients. ... Corlanor is thought to work by decreasing heart rate and represents the first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics